Incannex Healthcare

IXHL · NASDAQ

$2.64+$0.04 (+1.54%)TodayMarket closed ·
Prev close $2.60

Latest news

  • Press releaseGlobe Newswire

    Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position

  • Press releaseGlobe Newswire

    Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

  • Press releaseGlobe Newswire

    Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026

  • News

    Incannex Healthcare Begins Participant Screening In Its DReAMzz Phase 2 Dose Confirmation Study Evaluating IHL-42X To Treat Obstructive Sleep Apnea

  • Press releaseGlobe Newswire

    Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

  • Press releaseGlobe Newswire

    Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea

  • Press releaseGlobe Newswire

    Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility

  • Press releaseGlobe Newswire

    Incannex Announces Initiation of Research Coverage by Alliance Global Partners

  • Press releaseGlobe Newswire

    Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea

  • Press releaseGlobe Newswire

    Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • News

    12 Health Care Stocks Moving In Thursday's Intraday Session

  • NewsAvi Kapoor

    Crude Oil Surges Over 8%; Dollar General Shares Fall After Q4 Results

  • NewsAvi Kapoor

    Dow Tumbles Over 1%; US Weekly Jobless Claims Fall

  • News

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • News

    Incannex Healthcare Q2 Earnings Assessment

  • News

    12 Health Care Stocks Moving In Thursday's After-Market Session

  • News

    12 Health Care Stocks Moving In Tuesday's After-Market Session

  • NewsChris Katje

    EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank?

  • News

    12 Health Care Stocks Moving In Friday's Intraday Session

  • Press releaseGlobe Newswire

    Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

  • NewsChris Katje

    EXCLUSIVE: July's 20 Most-Searched Tickers On Benzinga Pro — Where Do Opendoor, Nvidia, Apple Stock Rank?

  • NewsAvi Kapoor

    Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

  • NewsAvi Kapoor

    Why Meta Platforms Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

  • NewsAvi Kapoor

    Gold Falls Over 1%; Phillips 66 Posts Upbeat Earnings

  • NewsAvi Kapoor

    US Stocks Higher; Charter Communications Shares Plunge After Q2 Results

  • NewsRishabh Mishra

    US Stocks Likely To Open Higher After S&P 500's Four-Day Fall: 'Market Is Risk-Off,' Says Expert

  • NewsRishabh Mishra

    Wall Street Poised To Open Higher After S&P 500's 4-Day Run: 'Sounds Like Powell Is Expecting More Frequent Bouts Of Stagflation,' Cautions Expert (CORRECTED)

  • NewsAvi Kapoor

    Dow Edges Higher; US Crude Oil Inventories Increase

  • NewsAvi Kapoor

    Nasdaq Gains Over 100 Points; Sony Group Posts Upbeat Earnings

  • NewsAvi Kapoor

    US Stocks Mixed; Coca-Cola Posts Upbeat Earnings

  • NewsPatricio Liddle

    Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies

  • NewsJuan Spínelli

    FDA Clears Incannex To Proceed With Phase 2 Psilocybin-Assisted Therapy Trial For Anxiety

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.